Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine Cancer Institute, Tongji University, No 507 Zhengmin Road, Shanghai 200433, People's Republic of China.
Cell Biochem Biophys. 2012 Nov;64(2):155-60. doi: 10.1007/s12013-012-9384-8.
Previous studies have revealed that EGFR mutation and/or EML4-ALK gene fusion rate was higher in the non-smoker Asian females with pulmonary adenocarcinoma. The aim of this study is to determine the distribution of known oncogenic driver mutations in the female non-smoker Asian patients with pulmonary adenocarcinoma. 104 consecutively resected lung adenocarcinomas from 396 non-smoker females (less than 100 cigarettes in a lifetime) at a single institution (Tongji University, Shanghai, China) were analyzed for mutations in EGFR, EML4-ALK, KRAS, HER2, BRAF, and PIK3CA. 73 (70.2 %) tumors harbored EGFR mutations; among these, 28 were deletions in exon 19, 44 were L858R missense changes, and eight were T790M mutations. 10 (9.6 %) harbored EML4-ALK fusions, two harbored KRAS mutations, two harbored BRAF mutations, and two harbored PI3K mutations. A majority of the mutations were mutually exclusive, except two with EGFR mutation and BRAF mutation, one with EML4-ALK fusions and PI3K mutation. Thus, 82.7 % (86 of 104; 95 % CI, 75.4-90.0 %) of lung adenocarcinomas from non-smoker females were found to harbor the well-known oncogenic mutations in five genes. Lung cancer in non-smoking Asian females is a distinct entity, with majority of this subgroup being developed by the oncogenic mutations. The prospective mutation examination in this population will be helpful for devising a targeted therapy for a majority of the patients.
先前的研究表明,非吸烟的亚洲女性肺腺癌患者中 EGFR 突变和/或 EML4-ALK 基因融合率较高。本研究旨在确定女性非吸烟亚洲肺腺癌患者中已知致癌驱动基因突变的分布。对一家机构(中国上海同济大学)连续切除的 396 例非吸烟女性(终生吸烟少于 100 支)的 104 例肺腺癌进行 EGFR、EML4-ALK、KRAS、HER2、BRAF 和 PIK3CA 基因突变分析。73 例(70.2%)肿瘤存在 EGFR 突变;其中 28 例为 19 外显子缺失,44 例为 L858R 错义改变,8 例为 T790M 突变。10 例(9.6%)存在 EML4-ALK 融合,2 例存在 KRAS 突变,2 例存在 BRAF 突变,2 例存在 PI3K 突变。大多数突变是相互排斥的,除了 2 例存在 EGFR 突变和 BRAF 突变,1 例存在 EML4-ALK 融合和 PI3K 突变。因此,82.7%(104 例中的 86 例;95%CI,75.4-90.0%)的非吸烟女性肺腺癌存在 5 个基因中的已知致癌突变。不吸烟的亚洲女性肺癌是一个独特的实体,大多数亚组由致癌突变引起。对该人群进行前瞻性突变检测将有助于为大多数患者制定靶向治疗方案。